282 related articles for article (PubMed ID: 25515960)
21. PAX5 fusion genes in acute lymphoblastic leukemia: A literature review.
Fouad FM; Eid JI
Medicine (Baltimore); 2023 May; 102(20):e33836. PubMed ID: 37335685
[TBL] [Abstract][Full Text] [Related]
22. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5.
Bousquet M; Broccardo C; Quelen C; Meggetto F; Kuhlein E; Delsol G; Dastugue N; Brousset P
Blood; 2007 Apr; 109(8):3417-23. PubMed ID: 17179230
[TBL] [Abstract][Full Text] [Related]
23. PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia.
Dang J; Wei L; de Ridder J; Su X; Rust AG; Roberts KG; Payne-Turner D; Cheng J; Ma J; Qu C; Wu G; Song G; Huether RG; Schulman B; Janke L; Zhang J; Downing JR; van der Weyden L; Adams DJ; Mullighan CG
Blood; 2015 Jun; 125(23):3609-17. PubMed ID: 25855603
[TBL] [Abstract][Full Text] [Related]
24. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
25. FOXP1 and PAX5 are rare but recurrent translocations partners in acute lymphoblastic leukemia.
Put N; Deeren D; Michaux L; Vandenberghe P
Cancer Genet; 2011 Aug; 204(8):462-4. PubMed ID: 21962897
[TBL] [Abstract][Full Text] [Related]
26. Identification of SPAG9 as a novel JAK2 fusion partner gene in pediatric acute lymphoblastic leukemia with t(9;17)(p24;q21).
Kawamura M; Taki T; Kaku H; Ohki K; Hayashi Y
Genes Chromosomes Cancer; 2015 Jul; 54(7):401-8. PubMed ID: 25951811
[TBL] [Abstract][Full Text] [Related]
27. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
[TBL] [Abstract][Full Text] [Related]
28. Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia.
Liu GJ; Cimmino L; Jude JG; Hu Y; Witkowski MT; McKenzie MD; Kartal-Kaess M; Best SA; Tuohey L; Liao Y; Shi W; Mullighan CG; Farrar MA; Nutt SL; Smyth GK; Zuber J; Dickins RA
Genes Dev; 2014 Jun; 28(12):1337-50. PubMed ID: 24939936
[TBL] [Abstract][Full Text] [Related]
29. A novel PAX5 rearrangement in TCF3-PBX1 acute lymphoblastic leukemia: a case report.
Barbosa TC; Lopes BA; Blunck CB; Mansur MB; Deyl AVS; Emerenciano M; Pombo-de-Oliveira MS
BMC Med Genomics; 2018 Dec; 11(1):122. PubMed ID: 30563523
[TBL] [Abstract][Full Text] [Related]
30. The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells.
Monni R; Santos SC; Mauchauffe M; Berger R; Ghysdael J; Gouilleux F; Gisselbrecht S; Bernard O; Penard-Lacronique V
Oncogene; 2001 Feb; 20(7):849-58. PubMed ID: 11314018
[TBL] [Abstract][Full Text] [Related]
31. Genomic profiling of B-progenitor acute lymphoblastic leukemia.
Mullighan CG
Best Pract Res Clin Haematol; 2011 Dec; 24(4):489-503. PubMed ID: 22127311
[TBL] [Abstract][Full Text] [Related]
32. Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression.
McClure BJ; Heatley SL; Kok CH; Sadras T; An J; Hughes TP; Lock RB; Yeung D; Sutton R; White DL
Br J Cancer; 2018 Apr; 118(7):1000-1004. PubMed ID: 29531323
[TBL] [Abstract][Full Text] [Related]
33. PAX5-ESRRB is a recurrent fusion gene in B-cell precursor pediatric acute lymphoblastic leukemia.
Marincevic-Zuniga Y; Zachariadis V; Cavelier L; Castor A; Barbany G; Forestier E; Fogelstrand L; Heyman M; Abrahamsson J; Lönnerholm G; Nordgren A; Syvänen AC; Nordlund J
Haematologica; 2016 Jan; 101(1):e20-3. PubMed ID: 26494837
[No Abstract] [Full Text] [Related]
34. Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.
Yu V; Pistillo J; Archibeque I; Han Lee J; Sun BC; Schenkel LB; Geuns-Meyer S; Liu L; Emkey R
Exp Hematol; 2013 May; 41(5):491-500. PubMed ID: 23340136
[TBL] [Abstract][Full Text] [Related]
35. Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study.
Coyaud E; Struski S; Prade N; Familiades J; Eichner R; Quelen C; Bousquet M; Mugneret F; Talmant P; Pages MP; Lefebvre C; Penther D; Lippert E; Nadal N; Taviaux S; Poppe B; Luquet I; Baranger L; Eclache V; Radford I; Barin C; Mozziconacci MJ; Lafage-Pochitaloff M; Antoine-Poirel H; Charrin C; Perot C; Terre C; Brousset P; Dastugue N; Broccardo C
Blood; 2010 Apr; 115(15):3089-97. PubMed ID: 20160164
[TBL] [Abstract][Full Text] [Related]
36. Infection Exposure is a Causal Factor in B-cell Precursor Acute Lymphoblastic Leukemia as a Result of Pax5-Inherited Susceptibility.
Martín-Lorenzo A; Hauer J; Vicente-Dueñas C; Auer F; González-Herrero I; García-Ramírez I; Ginzel S; Thiele R; Constantinescu SN; Bartenhagen C; Dugas M; Gombert M; Schäfer D; Blanco O; Mayado A; Orfao A; Alonso-López D; Rivas Jde L; Cobaleda C; García-Cenador MB; García-Criado FJ; Sánchez-García I; Borkhardt A
Cancer Discov; 2015 Dec; 5(12):1328-43. PubMed ID: 26408659
[TBL] [Abstract][Full Text] [Related]
37. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.
Kearney L; Gonzalez De Castro D; Yeung J; Procter J; Horsley SW; Eguchi-Ishimae M; Bateman CM; Anderson K; Chaplin T; Young BD; Harrison CJ; Kempski H; So CW; Ford AM; Greaves M
Blood; 2009 Jan; 113(3):646-8. PubMed ID: 18927438
[TBL] [Abstract][Full Text] [Related]
38. Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood.
Schmäh J; Fedders B; Panzer-Grümayer R; Fischer S; Zimmermann M; Dagdan E; Bens S; Schewe D; Moericke A; Alten J; Bleckmann K; Siebert R; Schrappe M; Stanulla M; Cario G
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28371317
[TBL] [Abstract][Full Text] [Related]
39. PAX5 alteration-associated gene-expression signatures in B-cell acute lymphoblastic leukemia.
Shang Z; Zhao Y; Zhou K; Xu Y; Huang W
Int J Hematol; 2013 May; 97(5):599-603. PubMed ID: 23529845
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
